Discussing proton pump inhibitor deprescribing: the views of Danish GPs and older patients
BMC Family Practice - 2020
Tóm tắt
Deprescribing of proton pump inhibitors (PPIs) can be considered in situations where the drug may no longer be necessary; however, this requires a careful discussion between patients and healthcare providers, often general practitioners (GPs). The aim of our study was to explore how GPs discuss PPI deprescribing with patients and compare that to how older patients would like to discuss this decision. We conducted a qualitative study using semi-structured interviews with GPs (n = 11) and patients aged ≥65 years who were taking PPIs (n = 4). Analysis of interviews was based on systematic text condensation. We identified four main themes: (1) Reasons PPI deprescribing comes up, (2) Considering PPI deprescribing, (3) Discussion topics, and (4) Incorporating patient preferences into PPI deprescribing decisions. We found that PPI deprescribing often comes up during consultations for other problems or due to concern about medication burden in general. GPs discussed topics related to symptom control, such as the possibility of rebound symptoms, the need to taper PPIs, and what to do if symptoms returned. This aligned with what patients felt was important to discuss. Some GPs routinely incorporated patient preferences into decisions, whereas others did not. When discussing PPI deprescribing, the GPs in our study generally focused on topics related to symptom control. There was variability in how and if patient preferences were discussed. Greater focus may be needed on developing mechanisms to elicit and incorporate patient preferences into PPI deprescribing decisions. Future research could also explore more systematic approaches to reassess ongoing PPI use in an effort to curb unnecessary long-term use of PPIs.
Từ khóa
Tài liệu tham khảo
Scarpignato C, Gatta L, Zullo A, Blandizzi C. Effective and safe proton pump inhibitor therapy in acid-related diseases – a position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179. https://doi.org/10.1186/s12916-016-0718-z.
Freedberg DE, Kim LS, Yang Y-X. The risks and benefits of Long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152(4):706–15. https://doi.org/10.1053/j.gastro.2017.01.031.
Farrell B, Pottie K, Thompson W, et al. Deprescribing proton pump inhibitors evidence-based clinical practice guideline. Can Fam Physician. 2017;63(5):354–64.
Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Ther Adv Gastroenterol. 2012;5(4):219–32. https://doi.org/10.1177/1756283X12437358.
Reeve E, Gnjidic D, Long J, Hilmer S. A systematic review of the emerging definition of “deprescribing” with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol. 2015. https://doi.org/10.1111/bcp.12732.
Hilmer SN, McLachlan AJ, Le Couteur DG. Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol. 2007;21(3):217–30. https://doi.org/10.1111/j.1472-8206.2007.00473.x.
Wastesson JW, Morin L, Tan ECK, Johnell K. An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf. 2018;17(12):1185–96. https://doi.org/10.1080/14740338.2018.1546841.
Jansen J, Naganathan V, Carter SM, et al. Too much medicine in older people? Deprescribing through shared decision making. Bmj. 2016;2893(June):i2893. https://doi.org/10.1136/bmj.i2893.
Turner JP, Richard C, Lussier MT, et al. Deprescribing conversations: a closer look at prescriber–patient communication. Ther Adv Drug Saf. 2018;9(12):687–98. https://doi.org/10.1177/2042098618804490.
Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–57. https://doi.org/10.1093/intqhc/mzm042.
Palinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K. Purposeful sampling for qualitative data collection and analysis in mixed method implementation research. Admin Pol Ment Health. 2015;42(5):533–44. https://doi.org/10.1007/s10488-013-0528-y.
Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open. 2014;4(12):e006544. https://doi.org/10.1136/bmjopen-2014-006544.
Thompson W, Black C, Welch V, Farrell B, Bjerre LM, Tugwell P. Patient values and preferences surrounding proton pump inhibitor use: a scoping review. Patient. 2017. https://doi.org/10.1007/s40271-017-0258-4.
Malterud K, Siersma VD, Guassora AD. Sample size in qualitative interview studies: guided by information power. Qual Health Res. 2015. https://doi.org/10.1177/1049732315617444.
Malterud K. Systematic text condensation: a strategy for qualitative analysis. Scand J Soc Med. 2012;40(8):795–805. https://doi.org/10.1177/1403494812465030.
Hendrix I, Page AT, Korhonen MJ, et al. Patterns of high-dose and Long-term proton pump inhibitor use: a cross-sectional study in six south Australian residential aged care services. Drugs Real World Outcomes. 2019;6(3):105–13. https://doi.org/10.1007/s40801-019-0157-1.
Mangin D, Risdon C, Lamarche L, et al. ‘I think this medicine actually killed my wife’: patient and family perspectives on shared decision-making to optimize medications and safety. Ther Adv Drug Saf. 2019;10:204209861983879. https://doi.org/10.1177/2042098619838796.
Muscat DM, Shepherd HL, Hay L, et al. Discussions about evidence and preferences in real-life general practice consultations with older patients. Patient Educ Couns. 2019;102(5):879–87. https://doi.org/10.1016/j.pec.2018.12.001.
Weir K, Nickel B, Naganathan V, et al. Decision-making preferences and Deprescribing: perspectives of older adults and companions about their medicines. J Gerontol Ser B. 2017. https://doi.org/10.1093/geronb/gbx138.
TrygFonden and Mandag Morgen. Sundhedsvæsenet Ifølge Danskerne.; 2016. https://www.trygfonden.dk/viden-og-materialer/publikationer/sundhedsvaesenet-ifoelge-danskerne.
Thompson W, Farrell B, Welch V, et al. Continuation or deprescribing of proton pump inhibitors: a consult patient decision aid. Can Pharm J. 2019;152(1):18–22. https://doi.org/10.1177/1715163518816719.
Fajardo MA, Weir KR, Bonner C, Gnjidic D, Jansen J. Availability and readability of patient education materials for deprescribing: an environmental scan. Br J Clin Pharmacol. 2019;85(7):1396–406. https://doi.org/10.1111/bcp.13912.
Maskrey N. Shared decision making: why the slow progress? An essay by Neal Maskrey. BMJ. 2019:l6762. https://doi.org/10.1136/bmj.l6762.
Jack E, Maskrey N, Byng R. SHERPA: a new model for clinical decision making in patients with multimorbidity. Lancet (London, England). 2018;392(10156):1397–9. https://doi.org/10.1016/S0140-6736(18)31371-0.
Haastrup PF, Thompson W, Søndergaard J, Jarbøl DE. Side effects of Long-term proton pump inhibitor use: a review. Basic Clin Pharmacol Toxicol. 2018;123(2):114–21. https://doi.org/10.1111/bcpt.13023.
Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. Ther Adv drug Saf. 2019;10:2042098618809927. https://doi.org/10.1177/2042098618809927.
Jarbøl DE, Lykkegaard J, Hansen JM, Munck A, Haastrup PF. Prescribing of proton-pump inhibitors: auditing the management and reasons for prescribing in Danish general practice. Fam Pract. 2019;36(6):758–64. https://doi.org/10.1093/fampra/cmz025.
Tandun R, Bubbar C, Tejani AM. Who has the guts to deprescribe proton pump inhibitors? A pharmacist-led intervention in a long-term care facility setting. Aging Med. 2019;2(2):112–7. https://doi.org/10.1002/agm2.12063.
Bundeff AW. Impact of clinical pharmacists’ recommendations on a proton pump inhibitor taper protocol in an ambulatory care practice. J Manag Care Pharm. 2013;19(4):325–33.